Iconix to Perform Toxicogenomic Research for Merck | GenomeWeb
NEW YORK (GenomeWeb News) - Iconix Pharmaceuticals today said it will use its in vitro toxicogenomic technology to assess drug safety for Merck in the early states of pre-clinical development.
Iconix's in vitro database includes gene-expression profiles on 119 compound treatments on primary rat hepatocytes.
Financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.